Cited 0 times in
LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T00:38:39Z | - |
dc.date.available | 2023-06-02T00:38:39Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194324 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | B.C. Cho | - |
dc.contributor.googleauthor | M-J. Ahn | - |
dc.contributor.googleauthor | J.H. Kang | - |
dc.contributor.googleauthor | R. Soo | - |
dc.contributor.googleauthor | T. Baisamut (Reungwetwattana) | - |
dc.contributor.googleauthor | J.C-H. Yang | - |
dc.contributor.googleauthor | I. Cicin | - |
dc.contributor.googleauthor | D-W. Kim | - |
dc.contributor.googleauthor | Y-L. Wu | - |
dc.contributor.googleauthor | S. Lu | - |
dc.contributor.googleauthor | K. Lee | - |
dc.contributor.googleauthor | Y-K. Pang | - |
dc.contributor.googleauthor | A. Zimina | - |
dc.contributor.googleauthor | C.H. Fong | - |
dc.contributor.googleauthor | E. Poddubskaya | - |
dc.contributor.googleauthor | Y. Kim | - |
dc.contributor.googleauthor | T. An | - |
dc.contributor.googleauthor | H. Lee | - |
dc.contributor.googleauthor | H. Byun | - |
dc.contributor.googleauthor | B. Zaric | - |
dc.identifier.doi | 10.1016/j.annonc.2022.10.349 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0923753422045409 | - |
dc.citation.volume | 33 | - |
dc.citation.number | Suppl 9 | - |
dc.citation.startPage | S1560 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Suppl 9) : S1560, 2022-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.